(Cagrilintide + semaglutide) is under clinical development by Novo Nordisk and currently in Phase III for Type 2 Diabetes. According to GlobalData, Phase III drugs for Type 2 Diabetes have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Cagrilintide + semaglutide)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Cagrilintide + semaglutide) overview
A fixed dose combination of cagrilintide and semaglutide is under development for the treatment of type 2 diabetes, obesity and metabolic dysfunction-associated steatohepatitis (MASH). It administered through subcutaneous route. Cagrilintide is a long-acting amylin analogue which acts by targeting calcitonin receptor, receptor activity modifying proteins 1, 2, 3 (RAMP 1-3) and semaglutide acts by targeting glucagon like peptide 1 receptor (GLP1R).
Novo Nordisk overview
Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company with focus on discovering, developing, and manufacturing biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious and chronic conditions including haemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for haemophilia; glucagon; and oral antidiabetic agents. The company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.
For a complete picture of (Cagrilintide + semaglutide)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
